@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "nizatidineoral solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer in most patients the ulcer will heal within 4 weeks nizatidineoral solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 15 mg h s after healing of an active duodenal ulcer the consequences of continuous therapy with nizatidine for longer than 1 year are not known nizatidine oral solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis including erosive and ulcerative esophagitis and associated heartburn due to gerd nizatidine oral solution is indicated for up to 8 weeks for the treatment of active benign gastric ulcer before initiating therapy care should be taken to exclude the possibility of malignant gastric ulceration in pediatric patients nizatidine oral solution is indicated for ages 12 years and older nizatidine oral solution is indicated for up to 8 weeks for the treatment of endoscopically diagnosed esophagitis including erosive and ulcerative esophagitis and associated heartburn due to gerd";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "g3LBJZrh126k5BIiQu4qjGWSQh5XufqmwF9sWiEyxzlQSwF0+T+xaiSiQDW0EN8IJOPzVZyc32+yIwweM38qUO+kUkUfAuU2xBCFtre3fa8c/9V1s+WtPu3Gy5TuhezWl6SRIUzuj7Ow2eAKCsPk99FVjH9V6af/zcuV908XX8Y=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-06-29T08:20:07.308+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}